Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Hebei gastrodin acupoint injection SNHL vertigo study

Also known as: Gastrodin Acupoint Injection, Gastrodin Injection, GAI SNHL vertigo study

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule/Acupoint Injection

Stage

Not applicable

Status

Completed

Target Gene

—

Route / Mode

Acupoint injection

Confidence

88%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

China

Population

adult, vertigo

Trial IDs

Mechanism

Randomized controlled trial of gastrodin acupoint injection as adjunctive therapy for sensorineural hearing loss with vertigo versus conventional therapy.

Indications

Sensorineural Hearing Loss Vestibular Disorders

Notes

Registry-verified institution-led adjunctive therapy study. This should be displayed as a study-level generic intervention, not a commercial pipeline product.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...

IDs: NCT07283562

Open

Key Events

2023-01-01

Gastrodin acupoint injection SNHL vertigo study started

2025-10-31

Study completed

Clinical Trials (1)